Probiotics for induction of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 3, 2020, Pages

  Kaur, Lakhbir ^a   Gordon, Morris ^a   Baines, Patricia Anne ^b   Iheozor Ejiofor, Zipporah ^a   Sinopoulou, Vasiliki ^a   Akobeng, Anthony K ^c  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b Sidra Medicine ^*  (United Kingdom)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MESALAZINE; PLACEBO; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISCOMFORT; ACNE; AGE DISTRIBUTION; ALOPECIA; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BLOATING; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DIZZINESS; DYSPEPSIA; ENDOSCOPY; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; ADOLESCENT; ADULT; CHILD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NUMBERS NEEDED TO TREAT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STATISTICAL BIAS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIAS; CHILD; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; HUMANS; MESALAMINE; MIDDLE AGED; NUMBERS NEEDED TO TREAT; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SAMPLE SIZE; SULFASALAZINE;

EID: 85081041578     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005573.pub3     Document Type: Review

References (61)

1. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology & Therapeutics 2004;20(10):1133-41. x-wiley/crsRef/12916406
2. Li K, Zhang CF, Xia YH, Li Z J, Han Y. Efficacy of probiotics on ulcerative colitis and it's mechanism. Zhonghua Weichang Waike Zazhi 2013;16(4):336-9. x-wiley/crsRef/12916408
3. Liu P, Sun L, Zhang ZH, Zhang P, Zhang J. Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis. World Chinese Journal of Digestology 2014;22:3344-8. x-wiley/crsRef/12916410
4. Matthes H, Krummernerl T, Giensch M, Wolff C, Schulze J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia Colu Nissle 1917. BMC Complementary and Alternative Medicine 2010;10:13. x-wiley/crsRef/12916412
5. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology 2009;104(2):437-43. x-wiley/crsRef/12916414
6. Olivia S, Di Nardo G, Aloi M, Falconieri P, Ferrari F, Mallardo S, et al. Rectal infusion of lactobacillus reuteri ATCC 55730 improves inflammation and down regulates mucosal pro-inflammatory cytokines in distal ulcerative colitis. Journal of Paediatric Gastroenterology and Nutrition 2011;52:E156. x-wiley/crsRef/12916416
7. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Eshcherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354(9179):635-9. x-wiley/crsRef/12916417
8. Sánchez-Morales A, Pérez-Ayala MF, Cruz-Martínez M, Arenas-Osuna J, Ramírez-Mendoza P, Ceniceros RA, et al. Probiotics’ effectiveness on symptoms, histological features and feeding tolerance in ulcerative colitis [Efectividad de probióticos sobre síntomas, histología y tolerancia alimentaria en colitis ulcerativa]. Revista Medica del Instituto Mexicano del Seguro Social 2019;57(1):9-14. x-wiley/crsRef/12916419
9. Solovyeva O. Probiotics can extend the remission of ulcerative colitis. Journal of Crohn's and Colitis 2014;8:S221. x-wiley/crsRef/12916421
10. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation VSL#3 induces remission in patients with mild-moderate active ulcerative colitis. Clinical Gastroenterology and Hepatology 2009;7(22):1202-9. x-wiley/crsRef/12916423
11. Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Digestive Endoscopy 2016;28(1):67-74. x-wiley/crsRef/12916425
12. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology 2010;105(10):2218-27. x-wiley/crsRef/12916427
13. Vejdani R, Bahari A, Zadeh AM, Azmi M, Ebrahimi-Daryani N, Hashtroudi AA, et al. Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: A placebo controlled study. Indian Journal of Medical Sciences 2017;69(1):24-8. x-wiley/crsRef/12916429
14. Zhang J. Effects of Bifidobacterium quadruplex live bacteria tablets on Mayo score and hs-CRP, IL-4, IL-8 in patients with mild to moderate ulcerative colitis. World Chinese Journal of Digestology 2018;26(6):373-7. x-wiley/crsRef/12916431
15. Ballini A, Santacroce L, Cantore S, Bottalico L, Dipalma G, Topi S, et al. Probiotics efficacy on oxidative stress values in inflammatory bowel disease: a randomized double-blinded placebo-controlled pilot study. Endocrine, Metabolic & Immune Disorders - Drug Targets 2019;19(3):373-81. x-wiley/crsRef/12916433
16. Bataga SM, Torok I, Macarie M, Negovan A, Botianu A. Rifaximine and probiotics in the treatment of mild relapse of left sided ulcerative colitis. European Journal of Clinical Investigation 2015;45:39-40. x-wiley/crsRef/12916435
17. Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology 2019;27:465-73. x-wiley/crsRef/12916437
18. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, et al. A randomized controlled trial on the efficacy of symbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009;25(5):520-5. x-wiley/crsRef/12916439
19. IRCT20120415009475N5. Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD) [Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD)]. www.irct.ir/trial/32179 Registration date 10 October 2018. x-wiley/crsRef/12916441
20. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition 2003;22(1):56-63. x-wiley/crsRef/12916442
21. Krag A, Munkholm P, Israelsen H, Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis - a randomized controlled trial. Inflammatory Bowel Disease 2013;19(12):2584-92. x-wiley/crsRef/12916444
22. NCT00374725. Treatment of ulcerative colitis with a combination of lactobacillus rhamnosus and lactobacillus acidophilus. www.clinicaltrials.gov/ct2/show/NCT00374725 (first received 11 September 2006). x-wiley/crsRef/12916446
23. NCT00895336. Lactobacillus GG in pediatric ulcerative colitis. clinicaltrials.gov/show/NCT00895336 (first received 8 May 2009). x-wiley/crsRef/12916448
24. Santana Porben S. Influence of a combination of lactobacilli and bifidobacteria upon disease activity, stool pattern and nutritional status of ulcerative colitis patients. Spanish society of parenteral and enteral nutrition 2010;25(6):971-83. x-wiley/crsRef/12916450
25. Turcotte JF, Huynh HQ. Treatment with the probiotic VSL#3 as an adjunctive therapy in relapsing mild-to-moderate ulcerative colitis significantly reduces ulcerative colitis disease activity. Evidence-Based Medicine 2011;16(4):108-9. x-wiley/crsRef/12916452
26. Fan H, Du J, Liu X, Zheng WW, Zhuang ZH, Wang CD, et al. Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. Turkish Journal of Gastroenterology 2019;30(8):680-5. x-wiley/crsRef/12916454
27. Fang W, Qingfeng C. Effect of mesalazine combined with bifid on inflammatory response and rectal-anal dynamics in patients with ulcerative colitis. World Chinese Journal of Digestology 2018;26(10):594-600. x-wiley/crsRef/12916456
28. Huang M, Chen Z, Lang C, Chen J, Yang B, Xue L, et al. Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors. Pakistan Journal of Pharmaceutical Sciences 2018;31(6):2891-5. x-wiley/crsRef/12916458
29. Shi XH, Tan FP, Jiang WH. Bacillus subtilis and Enterococcus faecium enteric-coated capsules combined with mesalazine for treatment of patients with ulcerative colitis: Efficacy and impact on serum levels of SOD, MDA, interleukins, and TNF-α. World Chinese Journal of Digestology 2018;26(12):748-54. x-wiley/crsRef/12916460
30. Yilmaz İ, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial. Turkish Journal of Gastroenterology 2019;30(3):242-53. x-wiley/crsRef/12916462
31. Zhang Y, Wu M, Chen Y. Effects of adjuvant therapy with bifidobacterium quadruplex on lipid peroxidation injury indexes, inflammatory factors and immune function in patients with ulcerative colitis. World Chinese Journal of Digestology 2018;26(22):1348-54. x-wiley/crsRef/12916464
32. NCT04006977. Multistrain Probiotics Reduces UC Depression and Anxiety Scores. clinicaltrials.gov/ct2/show/NCT04006977 First posted 5 July 2019. x-wiley/crsRef/12916466
33. Cohen RD. Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmaology and Therapeutics 2010;31(7):693-707.
34. Veritas Health Innovation. Covidence. Version accessed prior to 4 February 2020. Melbourne, Australia: Veritas Health Innovation.
35. Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al. Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology 2004;10(10):1521-5.
36. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;53(3):370-6.
37. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629.
38. Fabia R, Ar'Rajab A, Johannsson ML, Willen R, Andersson R, Molin G, et al. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scandinavian Journal of Gastroenterology 1993;28(2):155-62.
39. Fiorino G. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therapeutic Advances in Gastroenerology 2016;9(4):503-12.
40. McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.).
41. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Version 5.1.0. Available from www.handbook.cochrane.org: The Cochrane Collaboration 2011.
42. Kennedy RJ, Hoper M, Deodhar K, Kirk SJ, Gardiner KR. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scandinavian Journal of Gastroenterology 2000;35(12):1266-71.
43. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1997;11(5):853-8.
44. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23.
45. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004;126(6):1504-17. [PUBMED: 15168363]
46. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116(5):1107-14.
47. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121(3):580-91.
48. National Institute for Health and Care Excellence. Ulcerative Colitis Mangagement in adults, children and Young people CG166. NICE 2013. [https://www.nice.org.uk/guidance/ng130/evidence/june-2013-full-guideline-pdf-6777262190]
49. Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK. Probiotics to prevent infantile colic. Cochrane Database of Systematic Reviews 2019, Issue 3. [DOI: 10.1002/14651858.CD012473.pub2]
50. Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enterocolitis: New opportunities for translational research. Pathophysiology 2014;21(1):35-46.
51. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:1110-1.
52. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
53. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflammatory Bowel Diseases 2002;8(2):71-80.
54. Schünemann H, Hill S, Guyatt G, et al. The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology & Community Health 2011;65:392-5.
55. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflammatory Bowel Diseases 2002;8(6):399-406.
56. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. British medical journal 1955;2:1041.
57. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition 2018;62(2):257-91. [DOI: 10.1097/mpg.0000000000002035]
58. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative Colitis. Lancet 2017;389(10080):1756-70.
59. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23(11):1567-74.
60. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005573]
61. Mallon PT, McKay D, Kirk SJ, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005573]